P H Pritchard - JoVE Visualize

Showing results (111-120 of 113) with videos related to

Pageof 12

Sort By:

You have reached the last page of results.This site can display upto 113 results.

Journal of Molecular Medicine (Berlin, Germany)|October 30, 1999

Apolipoprotein A-I (R151C)Paris is defective in activation of lecithin: cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol effluxU Daum, C Langer, N Duverger, et al.

Journal of Lipid Research|September 19, 1998

Transmission of two novel mutations in a pedigree with familial lecithin:cholesterol acyltransferase deficiency: structure-function relationships and studies in a compound heterozygous probandG Argyropoulos, A Jenkins, R L Klein, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2005

The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)K M Wasan, P E Goss, P H Pritchard, et al.

Pageof 12

Showing results (111-120 of 113) with videos related to

Sort By:

Pageof 12

You have reached the last page of results.This site can display upto 113 results.

Journal of Molecular Medicine (Berlin, Germany)|October 30, 1999

Apolipoprotein A-I (R151C)Paris is defective in activation of lecithin: cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol effluxU Daum, C Langer, N Duverger, et al.

Journal of Lipid Research|September 19, 1998

Transmission of two novel mutations in a pedigree with familial lecithin:cholesterol acyltransferase deficiency: structure-function relationships and studies in a compound heterozygous probandG Argyropoulos, A Jenkins, R L Klein, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2005

The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)K M Wasan, P E Goss, P H Pritchard, et al.

Pageof 12